1. Introduction {#sec1}
===============

Autopsies of Chinese citizens who have died from COVID-19 following SARS-CoV-19 infection show evidence of interstitial changes, suggesting the development of pulmonary fibrosis \[[@bib1]\]. This suggests, at least partly, an autoimmunology basis of the pathogenesis of COVID-19. A number of causal bases of autoimmunity from exposure to viral epitopes is well established, whether the route of administration be by exposure via infection or vaccination. Systemic respiratory viral infections can have numerous serious health effects, including dyspnea, hypoxemia, dysuria, meningitis, low blood pressure, shock and death. Sequalae of viral infections can include various short-term and sometimes permanent effects on the central nervous system, via direct injury to CNS tissue due to viral replication (viral neuropathology) or due to the host immune system learning to attack CNS tissue (viral neuroimmunopathology). The public health consequences from some viruses can include impaired immunity, encephalitis, and long-term neurological diseases such as demyelinating disorders and relapsing events such as those seen in multiple sclerosis (MS).

Both genetic and environmental factors are thought to contribute both to the severity of viral infections, and in determining who will develop autoimmune conditions. Various specific mechanisms (etiologies) of autoimmunity are recognized as plausible in viral induction of autoimmunity, including epitope spreading, molecular mimicry, cryptic antigen, and bystander activation, each a plausible etiological mechanism responsible for activating self-reactive (SR) immune cells.

Mortality in SARS-CoV-2 infection from COVID-19 is highly age-dependent, with older patient having the highest probability of death. The etiology of the age-specific mortality seen in COVID-19 is largely unknown. SARS-CoV and SARS-CoV-2 coronaviruses targets the epithelial cells of the respiratory tract, resulting in diffuse alveolar damage. Other tissues are obviously also potential targets for viral immunopathology, including mucosal cells of the intestine, epithelial cells of the kidneys, brain cells (neurons), and cellular components of the immune system. In severe cases of SARS, and likely in SARS-CoV-2, this viral targeting leads acutely to pneumonia. Exposure to other viral and ambient antigens are known causal factors in chronic autoimmune diseases of the airways including asthma. The role of autoimmunity in enhancing the severity of secondary exposures following prior infection or vaccinations has been given little consideration.

Among coronaviruses, the spike surface glycoprotein is known to play a role in neuroimmunopathology. However, the SARS-CoV-2 virus has numerous other proteins and polyproteins, each which may serve as an antigen source during infection leading to autoimmunity. the immune system presents those proteins, like all human proteins, as "normal". T-cells are trained to recognize a normal protein shape in the thymus. Biomimicry between or among proteins from pathogens (infection or injection) can conflate the signaling by creating a population of memory B-cells, especially if the reaction switches from a Th-1 toward a Th-2 response.

In SARS, a type of "priming" of the immune system was observed during animal studies of SARS spike protein-based vaccines leading to increased morbidity and mortality in vaccinated animals who were subsequently exposed to wild SARS virus. The problem, highlighted in two studies, became obvious following post-vaccination challenge with the SARS virus \[[@bib2]\]. found that recombinant SARS spike-protein-based vaccines not only failed to provide protection from SARS-CoV infection, but also that the mice experienced increased immunopathology with eosinophilic infiltrates in their lungs. Similarly \[[@bib3]\], found that ferrets previously vaccinated against SARS-CoV also developed a strong inflammatory response in liver tissue (hepatitis). Both studies suspected a "cellular immune response".

These types of unfortunate outcomes are sometimes referred to as "immune enhancement"; however, this nearly euphemistic phrase fails to convey the increased risk of illness and death due to prior exposure to the SARS spike protein. For this reason, I refer to the concept as "pathogen priming"; the peptides with pathogenic potential therefore are referred to as "putative pathogenic priming peptides".

In this study, I present the likely human epitopic targets of biomimicry-induced autoimmunological components of morbidity and mortality caused by SARS-CoV-2 infection. This is achieved via bioinformatics analysis of the homology between highly immunogenic SARS-CoV-2 epitopes and human proteins to promote comprehension of the etiologies of pathogenesis of SARS-CoV-2 in COVID-19. Thirty-seven identified proteins in SARS-CoV-2 were evaluated.

2. Methods {#sec2}
==========

The investigative data analysis procedure included the following steps. First, for each ORF (open reading frame) reported as a canonical CDS (coding sequence) for the SARS-CoV-2 virus, flagged (significant) immunogenetic SARS-CoV-2 epitopes were found using SVMTriP (<http://sysbio.unl.edu/SVMTriP>; \[[@bib4]\]. These immunogenetic epitopes were then compared to human proteins using p-Blast (settings optimized for short sequences) against the *Homo sapiens* entries in the Protein Databank (<https://blast.ncbi.nlm.nih.gov/>). A list of human peptides with high local homology was compiled and their roles in the pathogenesis of COVID-19 from SARS-CoV-2 infection noted. The protein entries were mapped to nucleotide accession number, which were used to map as a gene set to pathways via Reactome ([Reactome.org](http://Reactome.org){#intref0020}). Tissue distribution of the targeted proteins was explored using the Protein Atlas ([ProteinAtlas.org](http://ProteinAtlas.org){#intref0025}).

3. Results {#sec3}
==========

Thirty-seven SARS-CoV-2 proteins were downloaded from the NCBI SARS-CoV-2 NCBI resource. Of these, 8 proteins had no recognizably immunogenic peptides. The remaining proteins had between one and six immunogenic peptides ([Table 1](#tbl1){ref-type="table"}). The proteins with the largest number of immunogenic peptides were the Spike, or S protein (N ​= ​6 in total), and the non-structural protein NS3 (also N ​= ​6; [Table 1](#tbl1){ref-type="table"}). All of the proteins had at least one match to human proteins except one, specifically nucleocapsid phosphoprotein (epitope 'QQQQGQTVTKKSAAEASKKP'), however even nucleocapsid phosphoprotein has one other epitope ('RRGPEQTQGNFGDQELIRQG') which has a localized match to the immunoglobulin heavy chain junction region (MOO20493; GNFGDQ).Table 1Protein[AccessionSARS-CoV-2 Protein NameImmunogenetic epitope(s)AccessionHuman Protein NamePutative pathogenic priming peptide (self-antigen)]{.ul}Tissue RNA/Protein Expression1QHN73821ORF1ab polyproteinRARTVAGVSICSTMTNRQFHCCO13833alternative protein TJP1TVICDTMLCPKVYFFTNRQFnearly ubiquitous(partial)CSTMTSRMCD32611**IHCJ**CSTMTSRB-cells, plasma cells2QHN73794ORF1ab proteinVATLQAENVTGLFKDCSKVINP_001339255la-related protein 4 (LARP4)EEVKGLFKSENCPKVIubiquitous3QIA98594ORF1ab polyproteinDRRATCFSTASDTYACWHHSAIT38911**IGJHCVR**DTYACWB-cells, plasma cellsDRRATCFSTASDTYACWHHSAGK29065**IGLCVR**DTYACWB-cells, plasma cellsDRRATCFSTASDTYACWHHSNP_001712cytoplasmic tyrosine-protein kinase BMX isoform 1ASDTYACWHepididymous4QIA98597ORF3a proteinYQIGGYTEKWESGVKDCVVLAAH82244PH domain and leucine rich repeat protein phosphatase 1(PHLPP1)GYTEASGVKNKLCVbrain, lung, kidney5QIA98604ORF7a proteinGVKHVYQLRARSVSPKLFIRXP_016871107sortilin related VPS10 domain containing receptor 1(SORCS1)GIKHVYQbrain, gastrointestinal tract, kidney6QIA98601ORF8 proteinFYSKWYIRVGARKSAPLIELEAX03800ankyrin repeat and sterile alpha motif domain containing 1A (ANKS1A)RVGVRKSAVPLeye, lung, gastrointestinal tract, liver7YP_009725310endoRNAseLIGEAVKTQFNYYKKVDGVV3SWR_ADNA methyltransferase 1VGEAVKTDGKKSYYKKVbrain, lung, gastrointestinal tract8YP_009725308helicaseATNYDLSVVNARLRAKHYVYMOQ41699**IHCJ**SVVAARLRPSHFDYB-cells, plasma cells9YP_009725297leader proteinLPQLEQPYVFIKRSDARTAP5SZF_L**Chain L, 2A10 antibody FAB fragment light chain**PYVFGGGTKLEIKRADAAPLPQLEQPYVFIKRSDARTAP3QXM_Aglutamate ionotropic receptor kainate type subunit 2 (GRIK2)LEEPYVLFKKSDbrain, kidney10QHO62114matrix proteinFIASFRLFARTRSMWSFNPEMCD74337**IHCJ**ARERSGWSFDPB-cells, plasma cells11QIA98599membrane glycoproteinFIASFRLFARTRSMWSFNPEMCD74337**IHCJ**ARERSGWSFDPB-cells, plasma cells12QIH45026M proteinFIASFRLFARTRSMWSFNPEMCD74337**IHCJ**ARERSGWSFDPB-cells, plasma cellsFIASFRLFARTRSMWSFNPEAAH80580pentatricopeptide repeat domain 1(PTCD1)RLFARARPMubiquitous13YP_009725298nonstructural protein NS2DGISQYSLRLIDAMMFTSDLNP_001165883VANGL planar cell polarity protein 1(VANGL1)GIVQYAVSLVDALLFubiquitous14YP_009725298nonstructural protein NS2VEKKKLDGFMGRIRSVYPVAEAW65335adaptor protein containing pH domain, PTB domain and leucine zipper motif 1, isoform CRA_aLVDAMMF15YP_009725299nonstructural protein NS3LGYVTHGLNLEEAARYMRSLAAC64695supervillin (SVIL)VTHRLLEEDTPRYMRubiquious except eye, bloodEEVGHTDLMAAYVDNSSLTIXP_016864345Rap guanine nucleotide exchange factor 2 (RAPGEF2)MASYVDNSbrain, bone marrow (RNA)EEVGHTDLMAAYVDNSSLTIXP_016864345Rap guanine nucleotide exchange factor 2 (RAPGEF2)ESSSLTbrain, bone marrow (RNA)QTTLKGVEAVMYMGTLSYEQANO56871**T-cell receptor beta chain variable region**MYLCASSLSYEQlung, bone marrow, bloodQTTLKGVEAVMYMGTLSYEQNP_001292017*N*-acetyltransferase 9 isoformGTEAVLAM\--LSYEspleenQVESDDYIATNGPLKVGGSCCAA56042protein-tyrosine-phosphataseDYIATQGPLKubiquitous16YP_009725300nonstructural protein NS4VHVMSKHTDFSSEIIGYKAIAIT39025**IGJHCVR**THFNSEIIGYB-cells, plasma cellsVHVMSKHTDFSSEIIGYKAI2W3C_ALGeneral vesicular transport factor P115IHVLQTDRSDSEIIGYskeletal muscle, others17YP_009725303nonstructural protein NS7GAVDINKLCEEMLDNRATLQ5VHJ_DProteasome 26S subunit, ATPase 4(PSMC4)GADINSICQESGMLAVRENRubiquitous18YP_009725304nonstructural protein NS8AVANGDSEVVLKKLKKSLNVAAI11491Bromodomain and WD repeat domain containing 3(BRWD3)VANGDGEVVubiquitous19YP_009725305nonstructural protein NS9AKVTSAMQTMLFTMLRKLDN1A4P_AS100 calcium binding protein A10(S100A10)AMETMMFTlung, bloodAKVTSAMQTMLFTMLRKLDNP0CL83Antigen 3-like protein 1MIFSMLRKL20YP_009725306nonstructural protein NS10TLKNTVCTVCGMWKGYGCSCEAW66814hCG1795641KGYGCSCTLKNTVCTVCGMWKGYGCSCEAW84736Cartilage oligomeric matrix proteinLKNTVMECDACGMadipose tissue, muscle21YP_009725307RNA-dependent RNA polymeraseQYIRKLHDELTGHMLDMYSVNP_001271153Elongator acetyltransferase complex subunit 3 (ELP3)FIRNLHDALSGHnearly ubiquitousMPNMLRIMASLVLARKHTTCXP_011508049Hedgehog acyltransferase (HHAT)MATLLARKHnearly ubiquitousDVNLHSSRLSFKELLVYAADXP_006713353Semaphorin 3F(SEMA3F)RLSFKELnearly ubiquitous22QIH45023S proteinLNEVAKNLNESLIDLQELGKEAW69281hCG23535KNLNQSLLDLHALGTLVKQLSSNFGAISSVLNDIXP_016871528Attractin-like protein 1FGAISSVLNDIbrainTLVKQLSSNFGAISSVLNDIXP_016871528Attractin-like protein 1AIASALIDIbrainQQLIRAAEIRASANLAATKMXP_011528323tetratricopeptide repeat protein 28QQLGIAEDLKDRAAEGRASSNubiquitousKEELDKYFKNHTSPDVDLGDXP_024309095follistatin-related proteinEILDKYFKNplacenta, most othersVMVTIMLCCMTSCCSCLKGCAAO32957Metallothionein 1E (MT1E)CKTSCCSCliver, most others23QIA98596Spike proteinLNEVAKNLNESLIDLQELGKXP_011535432Coiled-coil domain-containing protein 175 isoform X8KNMEEGLITLQELbrain, pituitary gland, testisTLVKQLSSNFGAISSVLNDIAAH27241ALDH1L1 proteinLVKNIQLEDGKMILASNFFKGAASSVLQQLIRAAEIRASANLAATKMXP_011528323Tetratricopeptide repeat protein 28 isoform X8QQLGIAEDLKDRAAEGRASSNLubiquitousKEELDKYFKNHTSPDVDLGDXP_024309095Follistatin-related protein 1 isoform X1EILDKYFKNplacenta, most othersVMVTIMLCCMTSCCSCLKGCNP_149050Keratin associated protein 4-7(KRTAP4-7)CCMSSCCskin24YP_0097253013C-like proteinaseAENVTGLFKDCSKVITGLHPAAH22377La ribonucleoprotein domain family member 4 (LARP4)EEVKGLFKSENCPKVIubiquitousHLSVDTKFKTEGLCVDIPGIXP_024308868TitinDTKFKTTGLDEGLheart muscle, skeletal muscle25QIA98602nucleocapsid phosphoproteinRRGPEQTQGNFGDQELIRQGMOO20493**IHCJ**GNFGDQB-cells, plasma cells26QHR63265nonstructural protein NS7aGVKHVYQLRARSVSPKLFIRXP_016871107VPS10 domain-containing receptor SorCS1GIKHVYQthyroid gland, many others27QHR63267nonstructural protein NS8FYSKWYIRVGARKSAPLIELAAH31934Ankyrin repeat and sterile alpha motif domain containing 1ARVGVRKSAVPLubiquitous28QIA98602nucleocapsid phosphoproteinQQQQGQTVTKKSAAEASKKPn/an/an/a29QIA98603ORF10 proteinMGYINVFAFPFTIYSLL- LCRMNSRNYIAQVDVVNFNLTn/an/an/a30QHR63254nonstructural protein NS6n/an/an/an/a31QHR63276nonstructural protein NS7bn/an/an/an/a32QHW06053orf6 proteinn/an/an/an/a33QIA20050ORF7b proteinn/an/an/an/a34YP_009725312nsp11n/an/an/an/a35YP_0097253112′-O-ribose methyltransferasen/an/an/an/a36YP_0097253093′-to-5′ exonucleasen/an/an/an/a37QIH45025E proteinn/an/an/an/a  immunoglobulin heavy chain junction region

Remarkably, over 1/3 (11/27) of the immunogenic proteins in SARS-CoV-2 have potentially problematic homology to proteins that are key to the human adaptive immune system (emboldened in [Table 1](#tbl1){ref-type="table"}). Mapping of the overall gene list to Pathways via [Reactome.org](http://Reactome.org){#intref0030} revealed that many functions of the human adaptive immune system might be impacted via autoimmunity against these proteins and their interactors, including MCH Class I and Class II antigen presentation, PD-1 signaling, cross-presentation of soluble exogenous antigens and the ER-Phagosome pathway.

4. Discussion {#sec4}
=============

These results could explain in part the high rates of serious illness associated with SARS-CoV-2. They could also explain the lengthy asymptomatic period prior to presentation of symptoms characteristic of COVID-19. SARS-CoV-2 could impair the immune response, at first, and then, over time, the immune system could begin to mount an attack on the myriad of proteins. Most of the identified human target proteins had low overall homology but high local homology over short segments of their epitopes. The Protein Atlas results indicated that numerous proteins are expressed in a variety of tissues as noted in [Table 1](#tbl1){ref-type="table"}.

Unintended consequences of pathogenesis from vaccines are not new, nor are they unexpected. They are unanticipated only if those who develop them do not include available knowledge in their formulation plan. For example, the H1N1 influenza vaccine used in Europe led to narcolepsy in some patients, resulting from homology between the human hypocretin (aka, orexin) receptor 2 molecule and proteins present in the vaccine. This was established via the detection of cross-reactive antibodies in the serum of patients who develop narcolepsy following H1N1 vaccination in Europe \[[@bib5]\].

The fact that pathogenic priming may be occurring involving autoimmunity against multiple proteins following CoV vaccination is consistent with other observations observed during autoimmunity, including the release of proinflammatory cytokines and cytokine storm. Similar to the SARS-CoV animal studies \[[@bib6]\], found that mice vaccinated against MERS-CoV (Middle East Respiratory Syndrome) development exaggerated pulmonary immunopathology when challenged with the MERS virus following vaccination. They reported that lung mononuclear infiltrates were observed in all groups after virus challenge, and that increased infiltrates that contained eosinophils and the eosinophil promoting IL-5 and IL-13 cytokines were observed only in the vaccinated animals.

Pathogenic priming may be more or less severe in vaccine or infection induced immune responses to some proteins than for others due to original antigenic sin; the immunologic reaction against self-antigens may be made less severe as fast-evolving viruses evolve away from the original vaccine type. Thus, the screening of immunogenic epitopes for pathogenic priming potential via homology may be augmented by studies of autoantibodies that cross-react with epitopes included in vaccines.

SARS-CoV-2 has some unexplained pathogenic features that might be related to the table of putative pathogenic priming peptides. Exposure to these specific peptides - via either infection or vaccination - might prime patients for increased risk of enhanced pathogenicity during future exposure due either to future pandemic or outbreaks or via universal vaccination programs. While the mechanisms pathogenesis of COVID-19 are still poorly understood, the morbidity and mortality of SARS has been extensively studied. Thus, the involvement of pathogenic priming in re-infection by COVID-19 is a theoretical possibility; of course no vaccine against SARS-CoV-2 has yet been tested in animals and therefore we do not yet know if pathogenic priming is in fact expected. Such studies should be undertaken before use of any vaccine against SARS-CoV-2 is used in humans.
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